Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

206 results about "Infection induced" patented technology

Monoclonal antibody for resisting staphylococcus aureus iron ion regulatory surface determinant B protein and application thereof

The invention discloses a monoclonal antibody for resisting staphylococcus aureus iron ion regulatory surface determinant B protein and application of the monoclonal antibody. Amino acid of a structural domain recognized by the monoclonal antibody is shown as SEQ ID NO.1. The monoclonal antibody is generated by culturing a host cell of an expression vector, the generated monoclonal antibody is secreted into supernate, and the supernate is secreted into the staphylococcus aureus iron ion regulatory surface determinant B protein to obtain the staphylococcus aureus iron ion regulatory surface determinant B. The staphylococcus aureus iron ion regulatory surface determinant B protein. Purifying through a chromatography technology; the obtained antibody can be used for treating septicopyemia caused by staphylococcus aureus / MRSA infection, and has important significance in preventing and treating staphylococcus aureus infection.
Owner:ARMY MEDICAL UNIV

Monoclonal antibodies with neutralizing activity against adenovirus type 5 and uses thereof

The present invention belongs to the field of virus detection technology, and specifically relates to monoclonal antibodies with neutralizing activity against adenovirus type 5 and their uses. The monoclonal antibody 8B9 of the present invention can specifically recognize and neutralize adenovirus type 5, and the amino acid sequences of the heavy and light chain variable regions and their complementarity determining regions of the monoclonal antibody 8B9 are provided. The present invention also provides an in vitro neutralization activity assessment model based on HEK-293A cells. At a concentration as low as 3.3 μg / mL, the titer of the neutralizing activity against the virus stock solution after 6000-fold dilution is 7×10 4 TCID 50 / mL of virus has close to 100% neutralizing activity. After further humanization, it is expected to be developed into a neutralizing antibody drug for the treatment of diseases such as severe pneumonia caused by HADV-5 infection, filling the current lack of effective treatment options in this field and possessing significant scientific research value and clinical application prospects.
Owner:BEIJING SUBENYUANHE BIOTECHNOLOGY CO LTD

Antibody for recognizing RSV pre-f protein and use thereof

The present invention relates to the field of immunology and molecular virology, and in particular relates to the field of the prevention and treatment of RSV. Specifically, provided are a monoclonal antibody capable of specifically binding to a new epitope between an Ø epitope and a V epitope on a pre-F protein or a new epitope between an II epitope and a V epitope, and the use thereof in the detection, prevention and / or treatment of RSV infection and / or diseases caused by the infections.
Owner:XIAMEN UNIV

Glucoside hydrolase with anti-biofilm activity and application thereof

The invention discloses glucoside hydrolase with anti-biofilm activity and application of the glucoside hydrolase. Experiments prove that the PgaBAb1 protein and the PgaBKp protein have remarkable anti-staphylococcus epidermidis biofilm activity and can destroy a mature staphylococcus epidermidis biofilm and inhibit formation of the staphylococcus epidermidis biofilm, that is, the PgaBAb1 protein and the PgaBKp protein are glucoside hydrolase with anti-biofilm activity; meanwhile, the sensitivity of the staphylococcus epidermidis to methicillin can be improved; the amino acid sequences of the PgaBAb1 protein and the PgaBKp protein are respectively as shown in SEQ ID NO: 5 and SEQ ID NO: 6. Therefore, both the PgaBAb1 protein and the PgaBKp protein can be used as active ingredients of drugs to treat diseases caused by infection of bacteria generating biological membranes and / or drug-resistant bacteria. The method has an important application value.
Owner:MEDICINE & BIOENG INST OF CHINESE ACAD OF MEDICAL SCI

Application of nigericin in preparation of anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) medicine

The invention provides an application of nigericin in preparation of an anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drug, and belongs to the technical field of antiviral drugs. Experimental results show that the nigericin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the nigericin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.
Owner:GIANTSTAR FARMING & ANIMAL HUSBANDRY CORP LTD

Application of wogonin in resisting siniperca chuatsi and frog iridovirus

The invention belongs to the technical field of biology, and discloses application of wogonin in resisting siniperca chuatsi and frog iridovirus, the wogonin can effectively inhibit over-generation of ROS caused by MRV virus infection, and oxidative stress damage of host cells is relieved in a dose-dependent mode. The wogonin can be used for preventing and treating the siniperca chuatsi and frog iridovirus, the high expression state of a proinflammatory gene can be reduced, intestinal tissue damage induced by MRV infection can be relieved, proliferation of MRV in the micropterus salmoides is effectively inhibited, the MRV challenge survival rate of the micropterus salmoides is increased, a basis is provided for preparing a product for resisting the siniperca chuatsi and frog iridovirus from wogonin, and the wogonin has important application value. Meanwhile, the invention also discloses a medicine, a fish feed and a fish feed additive of the wogonin.
Owner:INST OF ANIMAL HEALTH GUANGDONG ACADEMY OF AGRI SCI

Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient

The present invention relates to a composition for treatment of coronavirus disease 2019 (COVID-19) containing taurodeoxycholic acid (TDCA) or a pharmaceutically acceptable salt thereof as an active ingredient. Specifically, an early full recovery effect has been confirmed through the efficacy of treating clinical symptoms caused by novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, alleviating inflammation, and inhibiting inflammatory cytokines using a pharmaceutically acceptable salt of taurodeoxycholic acid, and thus the taurodeoxycholic acid or a pharmaceutically acceptable salt thereof can be used as an active ingredient in a composition for prevention or treatment of lower respiratory tract infectious diseases, including coronavirus disease 2019.
Owner:SHAPERON INC

RNA molecules

The present disclosure relates to RNA molecules encoding a respiratory syncytial virus (RSV) polypeptide. The present disclosure further relates to compositions comprising the RNA molecules formulated in a lipid nanoparticle (RNA-LNP). The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the treatment and / or prevention of RSV infection-induced acute respiratory tract illness, including pneumonia and bronchitis.
Owner:PFIZER INC

Primer probe group and kit for early detection of high-grade cervical lesions and cervical cancer

The invention provides a primer probe group and a kit for early detection of high-grade cervical lesions and cervical cancer. The nucleotide sequence of the primer probe group is as shown in any one of SEQ ID NO: 1-69; or a nucleotide sequence obtained by modifying, substituting, deleting or adding one or more basic groups to the nucleotide sequence as shown in any one of SEQ ID NO: 1-69, or a nucleotide sequence with similar functions to the nucleotide sequence as shown in any one of SEQ ID NO: 1-69. The primer probe group supports household sampling of cervical specimens, is combined with high-risk HPV and polygene methylation for joint detection, has high sensitivity and specificity, can quickly screen cervical cancer and high-grade lesions, reduces the omission ratio and improves the detection accuracy. Especially, cervical cancer and high-grade lesions caused by non-HPV infection and non-high-risk HPV infection which cannot be detected by other screening methods can be detected. Unnecessary referral treatment is reduced, the operation process is simplified, the time and economic cost of the examinee are reduced, and meanwhile the medical burden is relieved.
Owner:CUI ZHEN BIOTECHNOLOGY CO LTD (ZHENG ZHOU)

Antiviral composition comprising ginseng-based extract and steroid-based compound as active ingredients

The composition comprising a ginseng-based extract selected from the group consisting of a ginseng extract, a red ginseng extract, and a black ginseng extract and a steroid compound as active ingredients according to the present invention has a broad virus inhibitory activity, and thus can be used for effectively preventing, improving, or treating infections caused by viruses or diseases caused by infections.
Owner:真生巴伊帕

Application of sclareol in prevention and treatment of varicella-zoster virus infection

PendingCN120324390AHydroxy compound active ingredientsAntiviralsVaricella-zoster virus infectionCytopathic effect
The invention provides application of sclareol in preparation of a medicine for preventing and treating varicella-zoster virus infection. A series of biological experiments show that the sclareol can obviously relieve the cytopathic effect caused by VZV infection under the concentration without obvious cytotoxicity; the gene expression quantity of VZV characteristic genes including an immediate early gene ORF62, an early gene ORF21 and a late gene ORF68 and the expression of an early protein IE62 and a late protein gE can be remarkably inhibited, so that the effect of resisting VZV infection is achieved. The results show that sclareol has obvious prevention and treatment effects on VZV, has small toxic and side effects, is safe and effective, and has an application prospect in preparation of drugs for treating and / or preventing VZV.
Owner:ZHEJIANG HOSPITAL

Application of UH15-38 in preparation of medicine for preventing and treating PEDV-PoRVA co-infection

The invention belongs to the technical field of biological medicines, and particularly relates to application of UH15-38 in preparation of a medicine for preventing and treating PEDV-PoRVA co-infection. According to the invention, a PEDV and PoRVA co-infected piglet model is systematically established for the first time, a high-throughput transcriptomics means is combined, an enhancement mechanism of co-infection on host pathogenicity is deeply analyzed from an immune regulation level, and based on the mechanism, UH15-38 is found to be capable of effectively treating PEDV and PoRVA co-infected piglets. Experimental data show that the UH15-38 remarkably relieves clinical diarrhea symptoms caused by co-infection, reduces the copy number of PoRVA and PEDV viruses, effectively inhibits duplication of the viruses in intestinal tracts, remarkably reduces the expression levels of IL-1beta and p-MLKL in jejunum tissues, and reduces necrotic apoptosis and inflammatory response. The UH15-38 can provide a new application value for the treatment of the porcine viral diarrhea.
Owner:SUN YAT SEN UNIV

Anti-helicobacter pylori natural product composition and application thereof

The invention belongs to the technical field of application of natural products, and particularly relates to an anti-helicobacter pylori natural product composition and application, the anti-helicobacter pylori natural product composition comprises raspberry extract and cinnamon extract, and the composition contains anti-helicobacter pylori active substances. Besides, the natural product composition is combined with a clinical standard treatment method for treating helicobacter pylori, so that the curative effect can be further improved, and the gastrointestinal motility can be enhanced by adjusting intestinal flora disorder caused by pylorus infection, reducing toxic and side effects of antibiotic treatment, protecting gastric mucosa and enhancing gastrointestinal motility. The composition consists of two natural medicinal and edible plant extracts, is suitable for long-term use and has few adverse reactions. The Lycojaponicumin C can be used for preparing anti-helicobacter pylori medicines and preventive health-care foods, has obvious significance in prevention and treatment of helicobacter pylori infection, and has a good development prospect.
Owner:WUHAN POLYTECHNIC UNIVERSITY +1

Single traditional Chinese medicine powder spray for radically treating allergic rhinitis as well as preparation and application of single traditional Chinese medicine powder spray

The invention discloses a single traditional Chinese medicine powder spray for radically treating allergic rhinitis and preparation and application thereof.The single traditional Chinese medicine powder spray only contains gleditsia sinensis powder, is simple in composition and can temporarily stimulate epithelial cells to secrete normal nasal discharge to block and flush allergens, and nasal cavity flushing is achieved; the traditional Chinese medicine composition can change the local microenvironment of nasal mucosa and cut off the biological process of occurrence and development of allergic rhinitis, and enters the nasal mucosa to serve as a descaling agent, so that an IgE receptor Fc epsilon R1 on a sensitized mast cell membrane is separated from IgE and cannot be combined with allergens, and the mast cell cannot activate and release an allergic medium, so that the allergic rhinitis is radically treated; the preparation process of the single traditional Chinese medicine powder spray is simple and easy to operate, batch production can be realized, and after the saponin powder is processed by the alum, the astringency effect is remarkable, so that the clear water snot symptom of the allergic rhinitis can be improved; the nasal spray is used for treating allergic rhinitis, stimulates secretion of nasal discharge after being sprayed, and is beneficial to cleaning nasal cavities and improving nasal ventilation; the traditional Chinese medicine composition also has a sterilization function and can effectively inhibit bacterial and fungal infection induced by allergic rhinitis.
Owner:XI AN JIAOTONG UNIV

Peptide combination for the control of aldosterone synthesis in the function of pressure control and disorders due to infectious and other diseases

The present Invention relates to a newly designed product, i.e. substance (B+C) that combines two different mechanisms of action that allow the control of aldosterone synthesis and secretion without compromising the metabolism of cortisol (corticosterone In rats) in the.tone glomerulosa of the adrenal gland. The innovative design of the described molecule enables ths individual use of substance (B+C) in the treatment of diseases such as hyper and hypo aldosteronism, Conn's syndrome and cytokine storm caused by Covid infection or as co-therapy with corticosteroids in the treatment of a whole range of immunological diseases. The innovative design of Substance (8+C) has an additional practical and economic advantage because the patient receives both components of substance (B+C) simultaneously with just one application, regardless of the medicine formulation. This not only simplifies the medicine synthesis, dosing and clinical research, but also the application of the medicine in clinical practice. For successful and selective control of aldosterone synthesis, which in nature also means selective control of blood pressure, it was necessary to combine the two substances described in order to ensure action in patients with elevated and / or towered blood pressure with one application of Substance (B+C). This feature of Substance (B+C) is important, especially in the treatment of patients with permanently impaired aldosterone synthesis, such as Conn's disease and similar autoimmune diseases, or in combmatton with corticosteroids where prolonged or repeated corticosteroid therapy is indicated. Finally, this invention is extremely important because It enables the safe treatment of a large group of patients with hypertension who also have secondary diseases of the immune system, various inflammations or viral Infections such as Covid where corticosteroid therapy is indicated, but difficult to implement in practice due to the negative effect of corticosteroids on blood pressure.
Owner:ADEMOVIĊ, ZLATKO

Methods for treating diseases caused by HIV infection

It discloses a method for the treatment of disease caused by HIV infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound (1) or a pharmaceutically acceptable salt thereof.
Owner:ASCENTAGE PHARMA SUZHOU CO LTD +1

Antibodies that recognize RSV pre-F protein and uses thereof

summary The present invention relates to the field of immunology and molecular virology, in particular to the field of prevention and treatment of RSV, specifically to a monoclonal antibody capable of specifically binding to a new epitope between the Φ epitope and the V epitope on the pre-F protein, or between the II epitope and the V epitope, and its use in the detection, prevention and / or treatment of RSV infection and / or diseases caused by said infection.
Owner:XIAMEN UNIV

New application of tripterine in anti-inflammatory treatment of severe influenza A virus infection

The invention discloses a novel application of tripterine in anti-inflammatory treatment of severe influenza A virus infection. The invention relates to a novel application of tripterine in anti-inflammatory treatment of severe influenza A virus infection, and discloses that tripterine can effectively inhibit inflammatory response caused by severe influenza A virus infection and reduce pathological injury of lungs without affecting antiviral immune response.
Owner:THE FIRST AFFILIATED HOSPITAL OF ARMY MEDICAL UNIV +1

Use of carbonyl cyanide-4-trifluoromethoxyphenylhydrazone in the prevention and treatment of candida infections

PendingCN122461285ABiotechnologyCandida auris
The application discloses the use of carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone in the prevention and treatment of candida infection, belonging to the technical field of candida infection prevention and treatment. Carbon cyanogen - 4 trifluoromethoxy benzyl hydrazone is used as the only active ingredient for preparing a medicine for preventing or treating diseases caused by candida infection, wherein the candida is candida albicans and / or candida auris; or it is used for preparing a bacteriostatic and / or bactericidal product of candida, wherein the candida is candida albicans and / or candida auris. FCCP shows good inhibition of strain growth, good inhibition of biofilm effect and good mitochondria breaking effect in the antibacterial experiments of various candida (wild type candida albicans, drug resistant candida albicans and drug resistant candida auris). Thus, a new treatment drug for candida albicans and candida auris infection is provided.
Owner:ANHUI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE +1

Monoclonal antibody for resisting novel coronavirus and application thereof

The invention belongs to the technical field of biological medicine, and particularly relates to a monoclonal antibody for resisting novel coronavirus and application of the monoclonal antibody. In particular, the present invention relates to monoclonal antibodies against novel coronaviruses, as well as compositions (e.g., diagnostic and therapeutic agents) comprising the antibodies. In addition, the invention also relates to application of the antibody. The antibody of the invention can be used for diagnosing, preventing and / or treating infection of novel coronavirus and / or diseases caused by the infection.
Owner:SOUTHERN MEDICAL UNIVERSITY

Antibacterial protein composition for treating cow mastitis

The present invention relates to an antibacterial protein SBL200 having a bacteriolytic activity specific to Streptococci, and a method for preparing the antibacterial protein SBL200 having a bacteriolytic activity specific to Streptococci. More particularly, the present invention relates to: an antibacterial protein SBL200 specific for streptococcus, which is characterized by having an ability to specifically lyse streptococcus and having an amino acid sequence represented by SEQ ID NO: 1; and a composition for treating infection induced by streptococcus, which contains the antibacterial protein SBL200 specific for streptococcus as an active ingredient .
Owner:INTRON BIOTECHNOLOGY INC

CDP-choline a host-directed therapeutic for disease caused by SARS cov-2 infection

Compositions and methods are disclosed for treating coronavirus infections, such as SARS CoV-2 coronavirus infections. For example, a composition is disclosed that contains one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline (CDP-CHO), CDP-ethanolamine (CDP-ETH), and CDPdiacylglycerol (CDP-DAG) in combination with one or more agents for treating COVID-19, such as corticosteroids, antibodies, or antivirals, in a pharmaceutically acceptable carrier. Also disclosed is a method of treating coronavirus (e.g. SARS CoV-2) infection in a subject that involves administering to the subject one, two, or more cytidine diphosphate (CDP)-conjugated phospholipid precursors selected from the group consisting of CDP-choline (CDP-CHO), CDPethanolamine (CDP-ETH), and CDP-diacylglycerol (CDP-DAG) in combination with agents for treating COVID-19, such as corticosteroids, antibodies, or antivirals.
Owner:OHIO STATE INNOVATION FOUND

Application of periplocin in preparation of anti-PRRSV (porcine reproductive and respiratory syndrome virus) medicine

The invention provides application of periplocin in preparation of anti-PRRSV (Porcine Reproductive and Respiratory Syndrome Virus) drugs, and belongs to the technical field of antiviral drugs. Experimental results show that periplocin has extremely remarkable inhibiting and blocking effects on a 1-bit ribosome framing process of the PRRSV virus, and can be used for effectively inhibiting the replication of the PRRSV virus so as to inhibit the proliferation of the PRRSV virus; in addition, the compound has an extremely remarkable inhibition effect on the frame shift process of-1-bit ribosomes of different strains of PRRSV viruses; the periplocin can effectively inhibit replication and proliferation of PRRSV in vitro and in vivo of live pigs, can be used for preparing products for inhibiting proliferation of the PRRSV and can be used for preparing drugs for treating and preventing diseases caused by PRRSV infection, and the drugs are broad-spectrum anti-PRRSV drugs and have wide application prospects.
Owner:GIANTSTAR FARMING & ANIMAL HUSBANDRY CORP LTD

Hybrid protein, hybrid nucleotide sequence, nucleic acid molecule, vector for hybrid protein expression, use of hybrid protein or nucleotide sequence, formulation, process for producing a formulation and method for treating lesions and / or cancer caused by human papillomavirus (HPV) infection

PCT designated stage expiredWO2025039059A1Antibody mimetics/scaffoldsVirus peptidesNucleotideHybrid protein
The present invention describes an approach for improving immunogenic and therapeutic performance in the prevention and / or treatment of lesions and / or cancer caused by or associated with the human papillomavirus (HPV). More specifically, the approach involves a hybrid protein selected from two entities with improved immunogenic and therapeutic potential, use thereof and a formulation comprising same. Also disclosed are nucleotide sequences, a vector for the expression of recombinant proteins, as well as a process for producing a formulation comprising said entity and a therapeutic method. The invention applies to the fields of medicine, pharmacy and biotechnology.
Owner:IMUNOTERA THERAPEUTIC SOLUTIONS LTD

A traditional Chinese medicine composition for treating HPV infection, its preparation and uses.

This invention discloses a traditional Chinese medicine composition for treating HPV infection, its preparation, and its uses. The composition comprises the following ingredients in the indicated weight percentages: 10-40 parts of *Hedyotis diffusa*, 10-30 parts of *Smilax glabra*, 10-30 parts of *Hedyotis diffusa*, 10-30 parts of *Paeonia suffruticosa*, 10-40 parts of *Lithospermum erythrorhizon*, 10-30 parts of *Dictamnus dasycarpus*, 10-30 parts of *Radix Paeoniae Rubra*, 10-30 parts of *Cicadae Periostracum*, 10-30 parts of *Astragalus membranaceus*, and 10-30 parts of *Glycyrrhiza uralensis*. It effectively inhibits the replication of human papillomavirus (HPV) nucleic acid, thereby effectively treating cervical HPV infection caused by HPV, as well as infectious skin diseases such as cervical precancerous lesions and condyloma acuminata caused by HPV infection.
Owner:HANGZHOU BANGNI HEALTH TECH CO LTD

Cell-based formulation containing pluripotent stem cells for diseases or post-acute sequelae caused by SARS-cov-2 infection

This cell-based formulation contains SSEA-3-positive pluripotent stem cells derived from mesenchymal tissue of a living body or derived from cultured mesenchymal cells. This cell-based formulation is characterized in that the formulation is for administration to address diseases and / or post-acute sequelae caused by SARS-CoV-2 infection. The present invention makes it possible to provide a cell-based formulation that contains pluripotent stem cells and is used for treating and / or preventing SARS-CoV-2 infection-caused diseases such as pneumonia and pulmonary fibrosis and SARS-CoV-2 infection-caused post-acute sequelae such as olfactory dysfunctions.
Owner:FUJII JUN +1

A vaccine for the prevention of Escherichia coli infection and its application

This invention relates to a fusion protein, immunogenic composition, and recombinant vaccine for the prevention of Escherichia coli infection. The invention provides a novel target, PstS, for Escherichia coli vaccine design. Starting from the tertiary structure of PstS and YidR proteins, and combining immunoepitaxes, stable domains of PstS and YidR proteins and their variants are ultimately screened, leading to the construction of a fusion protein. Both the PstS monoantigen protein molecule and the PstS-YidR fusion protein molecule of this invention exhibit good immunogenicity, can reduce tissue lesions caused by Escherichia coli infection, and demonstrate high efficacy in preventing Escherichia coli infection, showing broad application prospects.
Owner:JIANGXI CHENGSHI BIOTECHNOLOGY CO LTD

Immunogenic compositions and uses thereof

The present disclosure relates to compositions comprising RNA molecules encoding an antigen derived from influenza, wherein the RNA may be formulated in a lipid nanoparticle (LNP), and wherein the composition further includes a polypeptide antigen derived from respiratory syncytial virus (RSV) and / or RNA molecules encoding an antigen derived from RSV, wherein the RSV RNA may be formulated in an LNP. The present disclosure further relates to the use of the RNA molecules, RNA-LNPs and compositions for the prevention of influenza and RSV infection-induced illness.
Owner:PFIZER INC

1-sulfonyl-3-amino-1 h-1,2,4-triazoles as yellow fever virus inhibitors

PCT designated stage expiredWO2025080695A1Heterocyclic compound active ingredientsArylAcyl group
Methods of inhibiting yellow fever virus (YFV) and treating diseases caused by YFV infections are described. For example, the methods can include administering a compound that includes a 1-sulfonyl-3-amino-1H-1,2,4-triazole group to a subject in need of treatment for yellow fever. The sulfonyl moiety of the l-sulfonyl-3-amino-1H-1,2,4-triazole group can be attached to a substituted or unsubstituted aryl group. For example, the sulfonyl moiety can be attached to a substituted or unsubstituted naphthyl moiety.
Owner:COLLABORATIONS PHARMACEUTICALS INC

Antigen-surface-coupled liposome vaccine for non-human animals

Disclosed is a vaccine for non-human animals, which vaccine enables effective immune induction in non-human animals such as livestock or poultry. The vaccine for non-human animals of the present invention comprises liposomes each comprising an antigen molecule(s) bound to the surface thereof, the antigen molecule(s) being derived from a pathogen infectious to the non-human animals. The non-human animals are, for example, livestock or poultry. One most preferred example of the vaccine according to the present invention is an infectious bronchitis virus (IBV) vaccine, which is effective against various isolated IBV strains, and which is expected to be sufficiently applicable even to cases where a mutant strain appeared. Another preferred example of the vaccine according to the present invention is a PRRSV vaccine, which was confirmed to have an effect that reduces fever, lung lesion development, and the like caused by the infection. The present invention enables development of liposome vaccines effective for prevention of infections caused by various non-human animal pathogens including PRRSV as well as IBV.
Owner:NAT FEDERATION OF AGRI COOP ASSOCS +1